Divis Laboratories Ltd

Divi's Lab. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Divis Laboratories Ltd

₹ 5,848 0.06%
23 Dec 4:01 p.m.
divislaboratories.com BSE: 532488 NSE: DIVISLAB
About

Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients[1]

Key Points

Business Overview:[1]
Company manufactures Generic Active pharmaceuticals ingredients, Custom synthesis of APIs & Intermediates along with Nutraceuticals for Global Pharmaceutical & Nutraceutical industry. These are segmented as:
a) Generic APIs:[2]
Company manufactures 30 Large Volume Generic APIs in 10’s to 100’s/1000’s of Tons each year and exports them to 100+ countries. Further, there are 10 APIs in various stages of R&D and pilot scale development
b) Custom Synthesis:[3]
Company under Custom Synthesis of APIs and Intermediates for global companies with a portfolio of products across diverse therapeutic areas. 12 out of top 20 Big Pharma Companies across US, EU and Japan have been associated with Divi’s for 10+ years
c) Nutraceutical:[4][5]
Company's Vishakhapatnam unit produces active ingredient and finished forms of Carotenoids. It is currently supplying carotenoids to all major food, dietary supplement and feed manufacturers globally. Company also offers customized ingredient solutions in liquids, beadlets and powder forms

Website BSE NSE
  • Market Cap ₹ 1,55,308 Cr.
  • Current Price ₹ 5,848
  • High / Low ₹ 6,449 / 3,350
  • Stock P/E 84.5
  • Book Value ₹ 514
  • Dividend Yield 0.51 %
  • ROCE 16.3 %
  • ROE 12.0 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 40.5%

Cons

  • Stock is trading at 11.4 times its book value
  • The company has delivered a poor sales growth of 9.45% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs

Part of BSE LargeCap BSE Dollex 200 Nifty Next 50 BSE 250 LargeMidCap Index BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
1,968 2,467 2,495 2,204 1,823 1,690 1,908 1,730 1,868 1,808 2,259 2,063 2,302
1,149 1,367 1,399 1,367 1,214 1,280 1,419 1,239 1,394 1,317 1,542 1,442 1,573
Operating Profit 819 1,100 1,096 837 609 409 489 491 474 491 717 621 729
OPM % 42% 45% 44% 38% 33% 24% 26% 28% 25% 27% 32% 30% 32%
19 17 51 90 79 116 66 80 85 94 79 79 105
Interest 0 0 0 -0 -0 0 -0 -0 1 -0 2 -0 1
Depreciation 77 80 81 83 85 87 87 93 94 95 94 97 98
Profit before tax 760 1,037 1,066 844 603 439 468 478 464 490 700 603 735
Tax % 20% 12% 17% 18% 19% 29% 32% 28% 26% 27% 24% 29% 30%
606 907 883 691 487 311 319 345 342 358 531 430 518
EPS in Rs 22.84 34.17 33.26 26.03 18.34 11.71 12.02 13.00 12.88 13.49 20.00 16.20 19.51
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
2,129 2,514 3,084 3,720 4,024 3,816 4,880 5,311 6,799 8,880 7,625 7,665 8,432
1,306 1,492 1,914 2,314 2,582 2,558 3,028 3,491 3,971 5,000 5,275 5,486 5,874
Operating Profit 823 1,022 1,170 1,406 1,441 1,258 1,851 1,820 2,828 3,880 2,350 2,179 2,558
OPM % 39% 41% 38% 38% 36% 33% 38% 34% 42% 44% 31% 28% 30%
49 81 36 92 73 106 155 187 57 109 348 333 357
Interest 3 3 3 4 3 2 5 7 2 2 2 4 3
Depreciation 77 92 136 118 123 142 169 186 255 311 342 376 384
Profit before tax 792 1,009 1,067 1,375 1,388 1,219 1,833 1,813 2,628 3,677 2,354 2,132 2,528
Tax % 23% 22% 21% 19% 24% 29% 27% 24% 26% 20% 23% 26%
611 792 847 1,111 1,053 870 1,333 1,373 1,955 2,949 1,808 1,576 1,837
EPS in Rs 23.03 29.82 31.90 41.84 39.68 32.76 50.20 51.71 73.63 111.07 68.11 59.37 69.20
Dividend Payout % 33% 34% 31% 24% 25% 31% 32% 31% 27% 27% 44% 50%
Compounded Sales Growth
10 Years: 12%
5 Years: 9%
3 Years: 4%
TTM: 17%
Compounded Profit Growth
10 Years: 7%
5 Years: 4%
3 Years: -7%
TTM: 39%
Stock Price CAGR
10 Years: 21%
5 Years: 26%
3 Years: 10%
1 Year: 58%
Return on Equity
10 Years: 20%
5 Years: 19%
3 Years: 18%
Last Year: 12%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 27 27 27 53 53 53 53 53 53 53 53 53 53
Reserves 2,527 3,008 3,535 4,304 5,356 5,907 6,920 7,264 9,218 11,638 12,652 13,431 13,582
33 18 27 42 36 63 106 34 0 -0 -0 -0 5
610 731 886 566 765 785 961 1,164 1,452 1,617 1,647 1,878 1,827
Total Liabilities 3,196 3,784 4,475 4,965 6,210 6,808 8,040 8,514 10,724 13,308 14,352 15,362 15,467
908 1,222 1,309 1,439 1,559 1,996 2,087 2,776 3,699 4,321 4,719 4,737 4,655
CWIP 303 144 218 264 444 120 492 920 711 470 212 778 1,316
Investments 411 505 736 813 1,639 1,897 1,953 979 7 79 84 89 92
1,573 1,913 2,212 2,450 2,568 2,795 3,508 3,839 6,307 8,438 9,337 9,758 9,404
Total Assets 3,196 3,784 4,475 4,965 6,210 6,808 8,040 8,514 10,724 13,308 14,352 15,362 15,467

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
483 558 822 1,036 1,149 765 964 1,208 1,947 1,910 2,447 1,266
-254 -305 -521 -411 -1,137 -476 -684 -81 75 -2,195 -2,707 -268
-231 -248 -303 -630 3 -314 -246 -1,091 -34 -532 -796 -798
Net Cash Flow -2 5 -1 -5 15 -25 34 36 1,988 -817 -1,056 200

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 96 115 97 95 91 106 96 105 94 106 94 108
Inventory Days 369 355 335 284 291 311 324 299 322 316 329 347
Days Payable 72 59 67 56 103 98 94 99 118 92 88 94
Cash Conversion Cycle 392 411 365 323 280 319 325 305 298 330 335 361
Working Capital Days 156 165 149 169 156 191 181 186 155 178 190 207
ROCE % 33% 36% 32% 35% 28% 21% 28% 24% 32% 35% 19% 16%

Shareholding Pattern

Numbers in percentages

8 Recently
Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
51.95% 51.94% 51.94% 51.94% 51.94% 51.94% 51.93% 51.93% 51.92% 51.92% 51.89% 51.89%
19.30% 18.45% 16.52% 15.40% 15.15% 14.67% 14.69% 14.60% 14.85% 14.68% 16.16% 17.25%
17.73% 18.32% 19.98% 20.75% 20.62% 21.00% 21.15% 21.65% 21.78% 22.10% 21.66% 20.98%
0.00% 0.00% 0.00% 0.03% 0.05% 0.07% 0.10% 0.10% 0.10% 0.10% 0.10% 0.09%
11.02% 11.28% 11.56% 11.88% 12.23% 12.31% 12.13% 11.72% 11.33% 11.19% 10.17% 9.79%
No. of Shareholders 2,74,5053,09,3973,46,9053,79,2574,14,8474,33,6214,02,1553,73,8603,54,4823,47,6292,98,3102,78,899

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls